Emerging therapies for thyroid carcinoma

Surgeon

Volumn 10, Issue 1, 2012, Pages 53-58

  Walsh, S ^a   Prichard, R ^a   Hill, A D K ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Anaplastic; BRAF; Imatinib; Medullary; Motesanib; Papillary; RET; Sorafenib; Sunitinib; Thyroid carcinoma; Tyrosine kinase inhibitors; Vandetanib

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ANAPLASTIC THYROID CANCER; HUMAN; METABOLISM; REVIEW; SIGNAL TRANSDUCTION; THYROID MEDULLARY CARCINOMA; THYROID TUMOR;

ANTINEOPLASTIC AGENTS; HUMANS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84855479978     PISSN: 1479666X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surge.2011.08.004     Document Type: Review

References (69)

1. Aschebrook-Kilfoy B., Ward M.H., Sabra M.M., Devesa S.S. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid 2011, 21:125-134.
2. Sipos J.A., Mazzaferri E.L. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 2010, 22:395-404.
3. Enewold L., Zhu K., Ron E., Marrogi A.J., Stojadinovic A., Peoples G.E., et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009, 18:784-791.
4. Hundahl S.A., Cady B., Cunningham M.P., Mazzaferri E., McKee R.F., Rosai J., et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000, 89:202-217.
5. Pacini F., Castagna M.G., Cipri C., Schlumberger M. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010, 22:475-485.
6. Kebebew E., Greenspan F.S., Clark O.H., Woeber K.A., McMillan A. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer 2005, 103:1330-1335.
7. Sherman S.I. Thyroid carcinoma. Lancet 2003, 361:501-511.
8. Cushing S.L., Palme C.E., Audet N., Eski S., Walfish P.G., Freeman J.L. Prognostic factors in well-differentiated thyroid carcinoma. Laryngoscope 2004, 114:2110-2115.
9. Haugen B.R. Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 1999, 16:34-41.
10. Namba H., Hara T., Tukazaki T., Migita K., Ishikawa N., Ito K., et al. Radiation-induced G1 arrest is selectively mediated by the p53-WAF1/Cip1 pathway in human thyroid cells. Cancer Res. 1995, 55:2075-2080.
11. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001, 344:1031-1037.
12. Paul B., Trovato J.A., Thompson J. Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. Am J Health Syst Pharm 2008, 65:1703-1710.
13. Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 2010, 20:697-706.
14. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005, 12:245-262.
15. Liu D., Liu Z., Jiang D., Dackiw A.P., Xing M. Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol Metab 2007, 92:4686-4695.
16. Ouyang B., Knauf J.A., Smith E.P., Zhang L., Ramsey T., Yusuff N., et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res. 2006, 12:1785-1793.
17. Ball D.W., Jin N., Rosen D.M., Dackiw A., Sidransky D., Xing M., et al. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab 2007, 92:4712-4718.
18. Carlomagno F., Santoro M. Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. J Chemother 2004, 16(Suppl. 4):49-51.
19. de Groot J.W., Links T.P., Plukker J.T., Lips C.J., Hofstra R.M. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev. 2006, 27:535-560.
20. De Vita G., Melillo R.M., Carlomagno F., Visconti R., Castellone M.D., Bellacosa A., et al. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival. Cancer Res. 2000, 60:3727-3731.
21. Phay J.E., Shah M.H. Targeting RET receptor tyrosine kinase activation in cancer. Clin Cancer Res. 2010, 16:5936-5941.
22. Carlomagno F., Vitagliano D., Guida T., Ciardiello F., Tortora G., Vecchio G., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002, 62:7284-7290.
23. Soh E.Y., Duh Q.Y., Sobhi S.A., Young D.M., Epstein H.D., Wong M.G., et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 1997, 82:3741-3747.
24. Ensinger C., Spizzo G., Moser P., Tschoerner I., Prommegger R., Gabriel M., et al. Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann N Y Acad Sci. 2004, 1030:69-77.
25. Westermark K., Lundqvist M., Wallin G., Dahlman T., Hacker G.W., Heldin N.E., et al. EGF-receptors in human normal and pathological thyroid tissue. Histopathology 1996, 28:221-227.
26. Di Carlo A., Mariano A., Pisano G., Parmeggiani U., Beguinot L., Macchia V. Epidermal growth factor receptor and thyrotropin response in human thyroid tissues. J Endocrinol Invest 1990, 13:293-299.
27. Wells S.A., Gosnell J.E., Gagel R.F., Moley J., Pfister D., Sosa J.A., et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010, 28:767-772.
28. Robinson B.G., Paz-Ares L., Krebs A., Vasselli J., Haddad R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010, 95:2664-2671.
29. Wells S.A., BGR, Gagel R.F., Dralle H., Fagin J.A., Santoro M., Baudin E., Vasselli J.R., Read J., Schlumberger M. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA). J Clin Oncol 2010, 28. abst 5508.
30. Carlomagno F., Anaganti S., Guida T., Salvatore G., Troncone G., Wilhelm S.M., et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006, 98:326-334.
31. Lam E.T., Ringel M.D., Kloos R.T., Prior T.W., Knopp M.V., Liang J., et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010, 28:2323-2330.
32. Frank-Raue K., Ganten M., Kreissl M.C., Raue F. Rapid response to sorafenib in metastatic medullary thyroid carcinoma. Exp Clin Endocrinol Diabetes 2011, 119:151-155.
33. Lipworth A.D., Robert C., Zhu A.X. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009, 77:257-271.
34. Chen L., Shen Y., Luo Q., Yu Y., Lu H., Zhu R. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. Thyroid 2011, 21:119-124.
35. Podtcheko A., Ohtsuru A., Tsuda S., Namba H., Saenko V., Nakashima M., et al. The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2003, 88:1889-1896.
36. Kurebayashi J., Okubo S., Yamamoto Y., Ikeda M., Tanaka K., Otsuki T., et al. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemother Pharmacol 2006, 58:460-470.
37. de Groot J.W., Zonnenberg B.A., van Ufford-Mannesse P.Q., de Vries M.M., Links T.P., Lips C.J., et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007, 92:3466-3469.
38. de Groot J.W., Zonnenberg B.A., Plukker J.T., van Der Graaf W.T., Links T.P. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 2005, 78:433-438.
39. Frank-Raue K., Fabel M., Delorme S., Haberkorn U., Raue F. Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 2007, 157:215-220.
40. Fenton M.S., Marion K.M., Salem A.K., Hogen R., Naeim F., Hershman J.M. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer. Thyroid 2010, 20:965-974.
41. Sweeney C.J., Chiorean E.G., Verschraegen C.F., Lee F.C., Jones S., Royce M., et al. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol 2010, 28:4513-4520.
42. Carr L.L., Mankoff D.A., Goulart B.H., Eaton K.D., Capell P.T., Kell E.M., et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010, 16:5260-5268.
43. Ravaud A., de la Fouchardiere C., Asselineau J., Delord J.P., Do Cao C., Niccoli P., et al. Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. Oncologist 2010, 15:212-213. author reply 4.
44. Torino F., Corsello S.M., Longo R., Barnabei A., Gasparini G. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009, 6:219-228.
45. Sherman S.I., Wirth L.J., Droz J.P., Hofmann M., Bastholt L., Martins R.G., et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008, 359:31-42.
46. Schlumberger M.J., Elisei R., Bastholt L., Wirth L.J., Martins R.G., Locati L.D., et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009, 27:3794-3801.
47. Bass M.B., Sherman S.I., Schlumberger M.J., Davis M.T., Kivman L., Khoo H.M., et al. Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J Clin Endocrinol Metab 2010, 95:5018-5027.
48. Kim L.C., Song L., Haura E.B. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol 2009, 6:587-595.
49. Wheeler D.L., Iida M., Dunn E.F. The role of Src in solid tumors. Oncologist 2009, 14:667-678.
50. Finn R.S. Targeting Src in breast cancer. Ann Oncol 2008, 19:1379-1386.
51. Schweppe R.E., Kerege A.A., French J.D., Sharma V., Grzywa R.L., Haugen B.R. Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab 2009, 94:2199-2203.
52. Stenner F., Liewen H., Zweifel M., Weber A., Tchinda J., Bode B., et al. Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer Sci. 2008, 99:1847-1852.
53. Mabuchi S., Kawase C., Altomare D.A., Morishige K., Sawada K., Hayashi M., et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res. 2009, 15:5404-5413.
54. Lu C.H., Wyszomierski S.L., Tseng L.M., Sun M.H., Lan K.H., Neal C.L., et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res. 2007, 13:5883-5888.
55. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res.70: 288-298.
56. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol.28: 1075-1083.
57. Bose S., Chandran S., Mirocha J.M., Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 2006, 19:238-245.
58. Alvarez RH, Valero V, Hortobagyi GN. Emerging targeted therapies for breast cancer. J Clin Oncol.28: 3366-3379.
59. Papewalis C., Wuttke M., Schinner S., Willenberg H.S., Baran A.M., Scherbaum W.A., et al. Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer. Horm Metab Res. 2009, 41:752-756.
60. Grozinsky-Glasberg S., Rubinfeld H., Nordenberg Y., Gorshtein A., Praiss M., Kendler E., et al. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells. Mol Cell Endocrinol 2010, 315:87-94.
61. Guigon C.J., Fozzatti L., Lu C., Willingham M.C., Cheng S.Y. Inhibition of mTORC1 signaling reduces tumor growth but does not prevent cancer progression in a mouse model of thyroid cancer. Carcinogenesis 2010, 31:1284-1291.
62. Chiacchio S., Lorenzoni A., Boni G., Rubello D., Elisei R., Mariani G. Anaplastic thyroid cancer: prevalence, diagnosisand treatment. Minerva Endocrinol 2008, 33:341-357.
63. Smallridge R.C., Copland J.A. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) 2010, 22:486-497.
64. Swaak-Kragten A.T., de Wilt J.H., Schmitz P.I., Bontenbal M., Levendag P.C. Multimodality treatment for anaplastic thyroid carcinoma-treatment outcome in 75 patients. Radiother Oncol 2009, 92:100-104.
65. Troch M., Koperek O., Scheuba C., Dieckmann K., Hoffmann M., Niederle B., et al. High efficacy of concomitant treatment ofundifferentiated (anaplastic) thyroid cancer withradiationand docetaxel. J Clin Endocrinol Metab 2010, 95:E54-E57.
66. Foote R.L., Molina J.R., Kasperbauer J.L., Lloyd R.V., McIver B., Morris J.C., et al. Enhanced survival in locoregionally confinedanaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 2011, 21:25-30.
67. Vrbic S., Pejcic I., Vrbic M., Filipovic S. Therapy of stage IV B anaplastic thyroid carcinoma: single institution experience. J BUON 2009, 14:41-44.
68. Yau T., Lo C.Y., Epstein R.J., Lam A.K., Wan K.Y., Lang B.H. Treatment outcomes in anaplastic thyroid carcinoma: survival improvement in young patients with localized disease reated by combination of surgery and radiotherapy. Ann Surg Oncol 2008, 15:2500-2505.
69. Ha H.T., Lee J.S., Urba S., Koenig R.J., Sisson J., Giordano T., et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 2010, 20:975-980.